viewMotif Bio PLC

Motif Bio PLC chief looking to add “one or two partners during 2016”

It has been a busy few months for Motif Bio PLC (LON:MTFB), the company behind next-generation antibiotic, iclaprim, and chief executive Graham Lumsden speaks to Proactive.

The firm recently passed a major milestone when it dosed its first patient in one of two phase III clinical trials it is carrying out, and just this week announced the appointment of specialist adviser, The Fulford Group to assist with the commercialisation of the treatment.

Lumsden says the company is looking for “one or two partners during 2016” to help commercialise iclaprim globally, and that the Fulford Group, which “specialises in finding partners for companies like Motif,” will aid the firm to do this.

Quick facts: Motif Bio PLC

Price: 0.27 GBX

Market: AIM
Market Cap: £1.31 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...



Motif Bio announces US FDA approval deadline for its antibiotic drug

Motif Bio (LON:MTFB, NASDAQ: MTFB) CEO Graham Lumsden tells Proactive Investors the US FDA has begun the process of assessing whether the company’s next-generation antibiotic should be allowed to go on sale in the US. Motif's drug iclaprim has been granted a priority review by the...

on 08/15/2018

2 min read